Insitro Inc.

https://www.insitro.com

insitro is a machine learning-enabled drug discovery and development company creating a new approach for target and drug discovery. We integrate multimodal data from human cohorts and cellular models with the power of AI and machine learning. insitro is uncovering genetic targets and new therapeutic hypotheses, leveraging human and cell data to increase the probability of success. These insights provide the starting point for discovering new molecules, which we either build with our in-house, AI-enabled drug discovery platforms or with partners that extend our impact. With more than $700 million in capital raised to date, insitro is building a "pipeline through platform" with a focus on metabolic disease, neurodegeneration and oncology. Approaching the clinic, insitro aims to deploy its AI models to run smaller, better powered trials, enrolling the patients who can benefit most. *

	Start	2018-01-01 established
	Industry	BIOTECH
	Industry 2	AI-based drug discovery / AI-based drug development
	Person	Koller, Daphne (Insitro 201904 CEO + Founder)
	Person 2	Rozenman, Mary (Insitro 202410 CFO + CBO)

	Region	South San Francisco, CA
	Country	United States (USA)
	Street	279 East Grand Avenue
	City	94080 San Francisco, CA
		Address record changed: 2024-10-06

Basic data	Employees	n. a.

		* Document for »About Section«: Insitro. (10/9/24). "Press Release: Insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases". South San Francisco, CA.

		Record changed: 2024-10-18